{"name":"Glycotope GmbH","slug":"glycotope-gmbh","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"immunology","drugs":[{"name":"Follitropin Epsilon","genericName":"Follitropin Epsilon","slug":"follitropin-epsilon","indication":"Induction of ovulation in women with polycystic ovary syndrome (PCOS) who do not ovulate","status":"phase_2"},{"name":"TrasGEX™","genericName":"TrasGEX™","slug":"trasgex","indication":"Other","status":"phase_1"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"CetuGEX™","genericName":"CetuGEX™","slug":"cetugex","indication":"Metastatic melanoma","status":"phase_2"}]}],"pipeline":[{"name":"CetuGEX™","genericName":"CetuGEX™","slug":"cetugex","phase":"phase_2","mechanism":"CetuGEX targets the CD137 receptor to stimulate an immune response against cancer cells.","indications":["Metastatic melanoma"],"catalyst":""},{"name":"Follitropin Epsilon","genericName":"Follitropin Epsilon","slug":"follitropin-epsilon","phase":"phase_2","mechanism":"Follitropin Epsilon is a recombinant human follicle-stimulating hormone used to stimulate follicular growth in the ovaries.","indications":["Induction of ovulation in women with polycystic ovary syndrome (PCOS) who do not ovulate","Assisted reproduction in women with diminished ovarian reserve"],"catalyst":""},{"name":"TrasGEX™","genericName":"TrasGEX™","slug":"trasgex","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.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?oc=5","date":"2025-01-16","type":"deal","source":"ET Pharma","summary":"Daiichi puts full faith in early-stage ADC, acquires IP rights for $132 Mn - ET Pharma","headline":"Daiichi puts full faith in early-stage ADC, acquires IP rights for $132 Mn","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirwFBVV95cUxOdmJ5QUJNOFp0WnIxdC1XU0ZxSmJyR3AyV1NuYnF6Sms5c2FodTc5R3JsWVl5TDlXWFhDMTFqV1ByYmtRSFZWOEdiWVlaSXRjbXlLaWc1a1J5QUlOdjFZLWJYaE9ydjdWVmRyY3Rfd2w4TU9KZ1A1TWdSbnBjTGJweWFUcTdmMFQ1bURrdkZneWhTLUZkdzc5dXJlaWJuN2Frc1Jyb2hRZEY1WHFKbEQw?oc=5","date":"2025-01-14","type":"deal","source":"Pharmaceutical Technology","summary":"Daiichi Sankyo buys solid tumour ADC from Glycotope for $132.5m - Pharmaceutical Technology","headline":"Daiichi Sankyo buys solid tumour ADC from Glycotope for $132.5m","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi-gFBVV95cUxOMkR2R0Frb3FXa3dGWFdFSWYxQkxEMGxaZ3E5Y2hGaFlPNF9NNmN2SmhOc2NzLThSR3Z6MEZYVkFVQXBiR2pNblN1NXpvcWVCTHBmWFNZM1BzSElxSHpHaDdBQ0lVcEE1aUFSR1NocG9hQkYwTjFZZTB0YTN1a0tiYkVyOUhkVGxaQzc5dWhFUFNBaUxJbjNXMmxaWkFWenF2NV9PVFRiWWtSX3hWRE5BSktfU21pcUNWa0dBaHpFaEVsdTJldUEzcG9hQVR4bktoQXk3RWVsYmpSR1BSZzFqblV4Ymtia1Uyd3VWMkFnc3haak1ldEh0Yk5B?oc=5","date":"2025-01-13","type":"deal","source":"businesswire.com","summary":"Daiichi Sankyo Acquires Intellectual Property Rights for Anti-TA-MUC1 Antibody in DS-3939 from Glycotope GmbH - businesswire.com","headline":"Daiichi Sankyo Acquires Intellectual Property Rights for Anti-TA-MUC1 Antibody in DS-3939 from Glycotope GmbH","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiogFBVV95cUxOUFltOHo2X0VMeVFDaDZBdVVCbi1jQ3pPeHdCN1BpaGdQb2VyUXBodFlmdUp0SlpZbm81emllS2p5NWV5RXRqZzR3Zko3TUVCOXBxUW5Ya2pYb3FCVEVZNlJfS291RFNUZXVkeEJhUFM4aG1yM25VRHMxTFBaZ1JYd1V6OFhZeDNkUkNDcEh2eHltV0FYUlloVy1kSzhOSnV6S1E?oc=5","date":"2024-09-30","type":"deal","source":"pharmaphorum","summary":"Closed and Collaborative: Mergers, acquisitions, and partnerships in July 2024 - pharmaphorum","headline":"Closed and Collaborative: Mergers, acquisitions, and partnerships in July 2024","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxNOXBvZnJEMG9ES182c1JNMWVvWWdRREVpc3NBWUtVMUM1cU5EcmprSWQtQ2U2SjJhdlNGZlM5WU5nMmFTSV9qbTg2WkdCWENUcnRYNlRfVEI0OFFHbFR3cnJKY0pCUjFmdkYxM0ZYMkNmM3pCbDFvY1YxamNOR21GWmVnMzNDT0hGelY5UDB4YWUwRzI4WVpUdg?oc=5","date":"2022-12-13","type":"pipeline","source":"Labiotech.eu","summary":"Therabest and Glycotope to assess breast cancer combination treatment - Labiotech.eu","headline":"Therabest and Glycotope to assess breast cancer combination treatment","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiogFBVV95cUxNYkNBZWFlX1F3MHNCNC13VG5jQ2FzWHZqdEtrRUczSXFuS1RQMEUtN2hFUmt4TGZicEpYNE00MkdQTHViY2V0eTAzR3hCUkpDX3JVZzFObFF1RTZvZTRWSDdZSzhuU2JEUk9oX1JsY1laM3c1S3JKcFVvbVg4ekRHUHZuekZIRDlRZk9ycTByQXFYS1Bfc2VQSFVILWdJellnZ2c?oc=5","date":"2022-07-12","type":"pipeline","source":"Labiotech.eu","summary":"Legochem Bioscience signs agreement with Glycotope to develop cancer drug - Labiotech.eu","headline":"Legochem Bioscience signs agreement with Glycotope to develop cancer drug","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqwFBVV95cUxQeVZSU0hGT19FbldSOXpqSl9YRU9oU2dnc1llaTdwQ0w4RUo4ZHpNcHJ4Zm5ZZEdiT3p0YmxFYWFuRnhHRHdQel9CUm5rUHR4MTBqMXlxb2wxNHNEaHVHOVgwc1BQNWNsd09wX2sxTzY5VHJDXzlTSFY3MGtONVVNX0s4bUVZUGMxMmM1MDdaUm1kQm5kUzlMbW94Q0VzcXhHS1F3cDZfSkV3OFE?oc=5","date":"2022-02-01","type":"pipeline","source":"Contract Pharma","summary":"Glycotope Spins-out Service Business to Newly Formed FyoniBio - Contract Pharma","headline":"Glycotope Spins-out Service Business to Newly Formed FyoniBio","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigAFBVV95cUxPVW5NbFl3Umo0c3pFWU5HZU54dzNZSDRpZWRsaHBzYWg0N3R4STdQQXFjVU5XelpGak8zdXNBOUswNlBQTGd6V09WbmFoYnhzMGo0Y2F1UVlINGN5TG0yU2tpMm9GZFRWSmNVUUItM05wdnFIb2VpWVVUQ0NEdWlJZQ?oc=5","date":"2011-06-12","type":"pipeline","source":"Pharmaceutical Technology","summary":"Glycotope Biotechnology Antibody Production Facility - Pharmaceutical Technology","headline":"Glycotope Biotechnology Antibody Production Facility","sentiment":"neutral"}],"patents":[],"drugCount":3,"phaseCounts":{"phase_2":2,"phase_1":1},"enrichmentLevel":0,"visitCount":5,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}